All News

    Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

    December 7th 2025, 7:58pm

    Article

    A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.

    Epkinly Combo Effective in Second-Line R/R Follicular Lymphoma

    December 7th 2025, 7:02pm

    Article

    The phase 3 EPCORE FL-1 trial showed that adding Epkinly to Rituxan and Revlimid delivered superior PFS and response rates.

    A New Option Without Traditional Chemotherapy for Ph+ ALL

    December 7th 2025, 6:49pm

    Article

    A new combination of Blincyto and Iclusig provided improved results and stronger responses for patients with Philadelphia chromosome-positive ALL compared with traditional chemotherapy.

    Azacitidine Plus Venclexta Superior to Chemo in Acute AML

    December 7th 2025, 5:47pm

    Article

    Among fit patients with acute myeloid leukemia, azacitidine plus Venclexta was shown to be superior to intensive chemotherapy.

    Older Patients With DLBCL May Benefit From First-Line Epkinly Plus R-mini-CHOP

    December 7th 2025, 4:45pm

    Article

    Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), Epkinly plus R-mini-CHOP appeared to be well tolerated and elicited responses.

    Higher Niktimvo Dosing Feasible in Chronic Graft-Versus-Host Disease

    December 7th 2025, 3:19pm

    Article

    Transitioning treatment with Niktimvo to a dose of 0.6 mg/kg every four weeks appeared feasible for chronic graft-versus-host disease.

    Black Patients With AML Face Lower Survival Outcomes

    December 7th 2025, 2:40pm

    Article

    Race has been identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

    KRd Improves Progression in Newly Diagnosed Patients With Myeloma

    December 7th 2025, 12:35am

    Article

    KRd improved progression-free survival, deepened responses, and led to higher MRD negativity versus VRd in patients with newly diagnosed multiple myeloma.

    Real-Time Text Tool Tracks Quality of Life in Myeloma Care

    December 7th 2025, 12:05am

    Video

    Real-time text check-ins helped physicians identify issues sooner and support quality of life for patients with myeloma at ASH 2025.

    Odronextamab Plus CHOP Shows Early Efficacy in DLBCL

    December 6th 2025, 10:55pm

    Article

    Among patients with previously untreated diffuse large B-cell lymphoma, odronextamab has been associated with early efficacy.